ADVERTISEMENT
Importance of Biomarker Testing and ADCs as a Novel Treatment Approach in Advanced/Metastatic NSCLC
Part 1
Highlights – Importance of Biomarker Testing
Four distinguished oncologists – Drs Corey Langer, Aaron Lisberg, Lyudmila Bazhenova, and Misako Nagasaka – describe biomarker testing in patients with advanced/metastatic NSCLC treated at their institutions. Topics include their use of internal vs external panels, the need for liquid biopsy in different settings, and the challenges of slow turnaround times in patients who don’t have time to wait for treatment.
Part 2
Biomarker Testing at the Time of Disease Progression
Having considered the basics of biomarker testing, our panelists turn their attention to challenges of biomarker testing at the time of NSCLC progression and share their perspectives on the current NCCN guidelines for biomarker testing and how they might be modified.
Part 3
Review of Targeted Therapies for Lung Cancer with Actionable Mutations
Drs Langer, Lisberg, Bazhenova, and Nagasaka describe their use of targeted therapies in patients with the most common mutations and fusions. They share their experiences with these agents both in clinical trials and in clinical practice.
Part 4
Antibody-Drug Conjugates (ADCs): Overview and Treatment Sequence
After sharing their basic approaches to treating actionable mutations, our 4 panelists now share their perspectives on the place of ADCs in advanced/metastatic NSCLC and on the future prospects of ADCs as a component of combination regimens and/or as a frontline therapy.
Part 5
Current Challenges and Unmet Needs in Targeted Treatment Selection
Drs Langer, Lisberg, Bazhenova, and Nagasaka conclude their discussion by considering remaining challenges in biomarker testing in NSCLC and unresolved questions about the appropriate place and future prospects of targeted treatments, including ADCs.
